Renaud Ronald C JR 4
4 · Kailera Therapeutics, Inc. · Filed Apr 20, 2026
Research Summary
AI-generated summary of this filing
Kailera (KLRA) CEO Renaud Ronald Jr Receives 600K Option Award
What Happened
Renaud Ronald C. Jr., CEO, President and a director of Kailera Therapeutics (KLRA), reported two awards of derivative securities on April 16, 2026 — each for 300,000 shares (total 600,000). The Form 4 lists each acquisition at $0.00 (derivative award), indicating stock option grants rather than an open‑market purchase or sale. These are grants (retention/incentive awards), not immediate sales.
Key Details
- Transaction date: 2026-04-16; filing date: 2026-04-20 (filed within the Form 4 two-business-day window).
- Award lines: two entries of 300,000 derivative securities each (total 600,000); price shown on the form = $0.00.
- Shares owned after transaction: not disclosed in the provided filing summary.
- Vesting/conditions:
- Award 1 (F1): 25% vests on April 16, 2027, then vests monthly in 36 substantially equal installments thereafter, subject to continued service.
- Award 2 (F2): performance‑based vesting — becomes exercisable for all underlying shares if (i) the 30‑day average Nasdaq closing price reaches or exceeds $40 during Oct 16, 2026–Apr 16, 2030, or (ii) a qualifying change‑in‑control occurs during that period; continued service required.
- Filing timeliness: appears timely (filed within required two business days).
Context
These entries are option awards (derivative grants), so they do not represent immediate ownership of additional common shares until vesting and exercise occur. Time‑based vesting is a standard retention mechanism; the second award includes a stock‑price performance hurdle ($40) that must be met during a specified period for vesting. No exercise or sale was reported in this Form 4.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-04-16+300,000→ 300,000 totalExercise: $16.00Exp: 2036-04-16→ Common Stock (300,000 underlying) - Award
Stock Option (right to buy)
[F2]2026-04-16+300,000→ 300,000 totalExercise: $16.00Exp: 2036-04-16→ Common Stock (300,000 underlying)
Footnotes (2)
- [F1]The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
- [F2]The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.